Released on = April 30, 2007, 5:10 am

Press Release Author = Bharat Book Bureau

Industry = Pharmaceuticals

Press Release Summary = \'The Autoimmune Inflammatory Bowel Disease Market Outlook to
2012\' is a new report from visiongain providing analysis of the current and future
market for IBD drugs across all major indications.

Press Release Body = \'The Autoimmune Inflammatory Bowel Disease Market Outlook to
2012\' is a new report from visiongain providing analysis of the current and future
market for IBD drugs across all major indications. Forecasts are given based on new
product launches, upcoming patent expiry dates, and ongoing clinical trials to
enable you to predict changes in the dynamics of the global IBD market. Autoimmune
disease is a multimillion dollar market set to increase as world prevalence rates
rise and the population lives longer. Inflammatory bowel disease (IBD) affect
millions of people worldwide with 2.8 million currently diagnosed with ulcerative
colitis (UC) or Crohn\'s disease (CD) in the US alone. The incidence of IBD is rising
in developing countries around the world. Currently the global market is estimated
at $16bn and this is set to continue to rise.

Historically, management of IBD with sulphonamides and corticosteroids did little to
alter the course of disease and had severe side effects. In the 1990\'s new therapies
were introduced in the form of enteric coated aminosalicylates (5-ASA). From 3
drugs and one target in 1993 there are now more than 30 products and 10 targets.
With the advent of monoclonal antibodies for use in IBD there has been a
breakthrough in disease management which is set to expand rapidly over the next few
years. Many more expensive biologicals are in the pipeline. As they gain approval
and are prescribed in favour of cheaper options, revenues in the IBD market will
grow rapidly.

- Will the current monoclonal blockbuster used to treat IBD continue to grow?
- What are the hottest research drugs in the pipeline?
- Will safety of issues restrict the use of biological agents in IBD?

Buy this report to find out!

Included in this report:

This report includes an up-to-date, analysis of IBD including the current market and
possible future developments. The following important issues are covered in detail:

What new anti-inflammatory drugs are seeking the IBD indication
Unique analysed forecast for the biologicals market for IBD, 2007-2012
Summaries and revenue forecasts for the leading 5-ASA drugs, 2007-2012
Summaries and revenue for monoclonal antibody drugs, 2007-2012
A thorough examination of the biological pipeline for IBD including cytokine,
chemokine and adhesion molecule antagonists
An assessment of future developments
You must order this report today.

Unique benefits to you when you order this report :

- Full searchable report when you buy the company or corporate editions
- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your
success for the forthcoming years. Order this report now.

Additional Information

Companies mentioned in the report

Abbott Laboratories
Amgen
Berlex Laboratories
Biogen Idec
Celltech
Chugai pharmaceuticals
Elan
Dr Falk
Ferring
Genentech
IVAX
Johnson & Johnson
Merck & Co
Millennium Pharmaceuticals, Inc.
Novartis
PDL Biopharma
Pfizer
Pharmacia
Procter & Gamble
Schering-Plough
Tanabe
Teva Pharmaceutical Industries
Roche
Salix Pharmaceutical
Sandoz
Santen Pharmaceutical
Sanofi-Aventis
Serono
Shire Pharmaceuticals Group
UCB
Wyeth

For more information, Please visit : http://www.bharatbook.com/detail.asp?id

Web Site = http://www.bharatbook.com

Contact Details = Bharat Book Bureau
207, Hermes Atrium, Navi Mumbai - 400 614, India.
Ph. : +91-(022)-2757 8668 or +91-(022)-2757 9131
email : bharatbook@gmail.com